204192-41-6

Basic information

• Product Name: 3'H-spiro[cyclohexane-1,1'-isobenzofuran]-4-one
• Synonyms: 3'H-spiro[cyclohexane-1,1'-isobenzofuran]-4-one
• CAS NO: 204192-41-6
• Molecular Weight: 202.253
• Mol File: 204192-41-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3'H-spiro[cyclohexane-1,1'-isobenzofuran]-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3'H-spiro[cyclohexane-1,1'-isobenzofuran]-4-one(204192-41-6)
• EPA Substance Registry System: 3'H-spiro[cyclohexane-1,1'-isobenzofuran]-4-one(204192-41-6)

Safety Data

• Hazardous Substances Data: 204192-41-6(Hazardous Substances Data)

Upstream product

• 204193-43-1 8-(2-(hydroxymethyl)phenyl)-1,4-dioxaspiro[4.5]decan-8-ol 
• 76-05-1 trifluoroacetic acid 
• 6630-33-7 ortho-bromobenzaldehyde 
• 1252607-62-7 [2-(1,4-dioxa-spiro[4.5]dec-7-en-8-yl)-phenyl]-methanol 
• 78988-21-3 3H-dispiro[2-benzofuran-1,1'-cyclohexane-4',2''-[1,3]dioxolane] 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 69225-59-8 3,3-dimethyl-1,5-dioxaspiro[5.5]undecan-9-one 
• 18982-54-2 o-bromobenzyl alcohol 

Downstream Products

• 204192-38-1 2-fluoro-4-(trans)-(4-(3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)piperazin-1-yl)benzonitrile 

Relevant articles and documents

Desymmetrizing Isomerization of Alkene via Thiazolinyl Iminoquinoline Cobalt Catalysis

We report a cobalt-catalyzed desymmetrizing isomerization of exo-cyclic alkenes to generate chiral 1-methylcyclohexene derivatives with good yields and enantioselectivities. A novel chiral thiazolinyl iminoquinoline ligand and its cobalt complex were desi

4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Spirocyclic dopamine receptor subtype ligands

This invention relates to novel, pharmaceutically active compounds of formula (I) wherein a, b and R1through R6are as defined in the specification These compounds exhibit central dopaminergic activity and are useful in the treatment